Treatment for Molluscum Contagiosum
Physical removal methods including incision and curettage, simple excision, excision and cautery, or cryotherapy are recommended as first-line therapy for molluscum contagiosum to prevent transmission and reduce associated symptoms. 1
Overview of Molluscum Contagiosum
- Molluscum contagiosum is a common, benign viral skin infection presenting as skin-colored, whitish, or pink papules with a central umbilication, typically affecting the trunk, face, and extremities in children and adolescents 2, 3
- The condition is caused by a poxvirus and is transmitted through direct skin contact, fomites, or self-inoculation 1
- Lesions typically persist for 6-12 months but can last up to 4-5 years without treatment 2, 4
- The condition is mostly asymptomatic but may present with pain, itching, redness, or occasional bacterial superinfection 2, 3
Treatment Options
First-Line Treatments
Physical removal methods:
Topical chemical treatments:
Important Considerations
- Cryotherapy may be associated with postinflammatory hyperpigmentation or, uncommonly, scarring 2
- Imiquimod has not shown benefit compared to placebo in randomized controlled trials for molluscum contagiosum and is not recommended 2, 6
- For lesions near the eyes with associated conjunctivitis, monitor for resolution of conjunctivitis after lesion removal 1
- In immunocompromised patients (especially those with HIV), lesions may be more extensive and persistent, potentially requiring treatment with cidofovir, imiquimod, or interferon 7
Treatment Algorithm
For limited disease in immunocompetent patients:
For extensive disease:
For genital lesions:
For pregnant patients:
- Physical procedures like cryotherapy are considered safe 7
For immunocompromised patients:
Common Pitfalls and Caveats
- Waiting for spontaneous resolution may be appropriate in some cases, but can take months to years and risks spread of lesions through autoinoculation 4
- Treatment should not be more burdensome than the disease itself; consider patient comfort and preferences 8
- Imiquimod, despite being used in clinical practice, failed to demonstrate efficacy in controlled studies and should not be considered a first-line treatment 2, 6
- In children with extensive disease, systemic absorption of topical treatments should be considered 6
- Follow-up is generally not necessary unless conjunctivitis persists or if lesions are extensive/recurrent 1